All In Biotech

NDA 021674 · Bayer Hlthcare

Menostar

Estradiol · Transdermal

Last checked: Nov 20, 2026Latest source record: Jun 8, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jun 8, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

47,042

22,534 serious, 909 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 8, 2004 Original approval · Type 6 - New Indication (no longer used) LetterLabelReview
1 products under this application
  • MENOSTAR · ESTRADIOL 0.014MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,830
  • headache2,889
  • nausea2,877
  • fatigue2,870
  • off label use2,399
  • pain2,081
  • diarrhoea1,955
  • dizziness1,728
  • breast cancer female1,708
  • arthralgia1,636
  • product adhesion issue1,582
  • pruritus1,558

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004524
2005571
2006406
20071,465
2008466
2009608
2010958
2011858
20121,156
2013879
20141,113
20151,912
20162,328
20172,136
20182,487
20192,872
20202,878
20212,831
20223,054
20233,554
20243,703
20255,251
20265,031

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Menostar (Estradiol)

2024 spending

$605K

Beneficiaries

432

1,679 claims

Per beneficiary

$1,401

$38.76 per unit

View as table
YearSpending
2020$704,281
2021$685,540
2022$651,121
2023$611,837
2024$605,353

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.